Nuvation Bio Inc.

NYSE:NUVB Stock Report

Market Cap: US$2.4b

Nuvation Bio Management

Management criteria checks 3/4

Nuvation Bio's CEO is David Hung, appointed in Apr 2018, has a tenure of 8.33 years. total yearly compensation is $3.88M, comprised of 16.8% salary and 83.2% bonuses, including company stock and options. directly owns 17.17% of the company’s shares, worth $411.72M. The average tenure of the management team and the board of directors is 4.1 years and 3.2 years respectively.

Key information

David Hung

Chief executive officer

US$3.9m

Total compensation

CEO salary percentage16.77%
CEO tenure8.3yrs
CEO ownership17.2%
Management average tenure4.1yrs
Board average tenure3.2yrs

Recent management updates

Recent updates

Narrative Update • Aug 13

NUVB: Safusidenib Glioma Data Will Drive Future Upside Potential

Analysts have nudged their average price target for Nuvation Bio higher from about $12.33 to roughly $13.11, citing recent safusidenib trial updates, upward revisions to individual targets as high as $21, and an expanded view of the long term glioma treatment opportunity. Analyst Commentary Recent Street research on Nuvation Bio focuses heavily on safusidenib data and how that might translate into future revenue potential and stock valuation.
Narrative Update • Jul 24

NUVB: Glioma Data And Lung Cancer Progress Will Shape Future Upside And Risks

Analysts have trimmed their fair value estimate for Nuvation Bio from $8.00 to $7.00 as they factor in a slightly higher discount rate, more moderate projected revenue growth, and updated views on long term profitability and future P/E, while also citing supportive safusidenib data and a revised $19 price target. Analyst Commentary on Nuvation Bio Recent research commentary on Nuvation Bio centers on updated safusidenib data and how that could influence long term valuation, especially in relation to the company’s revised fair value estimate and price target.
Narrative Update • Jul 10

NUVB: UK Regulatory Progress For Lead Oncology Asset Will Drive Future Upside

Analysts have adjusted their fair value estimate for Nuvation Bio to $12.33 from $10.25, citing updated assumptions on discount rates, future profitability and P/E expectations, alongside recent sector commentary around biotech earnings and capital flows. What’s in the News for Nuvation Bio Nuvation Bio reported that partner Eisai’s Marketing Authorisation Application for taletrectinib in advanced ROS1-positive non small cell lung cancer was validated by the UK Medicines and Healthcare products Regulatory Agency, moving the therapy into formal UK regulatory review (source: company announcement and partner Eisai).
Narrative Update • Jun 26

NUVB: Convertible Notes Raise Will Support Advancing Lead Oncology Portfolio

Analysts have lifted their price target on Nuvation Bio from about $16.80 to roughly $19.70, reflecting updated assumptions for revenue growth, profit margins, discount rate and future P/E that they see as better aligned with the company’s current outlook. What’s in the News for Nuvation Bio Nuvation Bio plans to raise up to US$230 million through a convertible senior notes offering maturing in 2032.
Seeking Alpha • Jun 15

Nuvation Bio: David Hung's Latest Venture Looks Undervalued At Current Level

Summary I initiate coverage of Nuvation Bio with a Moderate Buy, citing undervaluation based on two value-driving oncology assets. NUVB's fundamentals hinge on Ibtrozi (taletrectinib), a next-gen ROS1 inhibitor now commercial, and safusidenib, a late-stage mutant IDH1 inhibitor. My sum-of-the-parts analysis yields a $5.6/share fair value, with further upside from M&A potential, re-rating anchored on recent M&A activity, and milestone payments. Risks include Ibtrozi's revenue ramp, patent runway, and clinical uncertainty for safusidenib, but a strong balance sheet limits near-term dilution. Read the full article on Seeking Alpha
Analysis Article • May 08

Results: Nuvation Bio Inc. Confounded Analyst Expectations With A Surprise Profit

Investors in Nuvation Bio Inc. ( NYSE:NUVB ) had a good week, as its shares rose 8.1% to close at US$4.81 following the...
Analysis Article • May 17

Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Feb 13

Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst

Summary Nuvation Bio, listed via SPAC in 2021, and acquired AnHeart Therapeutics last year, gaining taletrectinib, a promising ROS1 inhibitor indicated for NSCLC. The FDA has accepted Nuvation's New Drug Application for the drug, assigning it priority review and a PDUFA date of June 23, 2025. Taletrectinib shows clearly superior clinical data compared to rivals, with a potential market opportunity of ~$3.8bn by its fourth year, despite current market skepticism. Concerns include reliance on Chinese study data and competition from established pharma giants, but Nuvation's cash reserves suggest readiness for a wide-scale launch. Ahead of the PDUFA date, Nuvation presents a speculative investment opportunity, given it is potentially undervalued with a "blockbuster-in-waiting" drug candidate so close to approval, and further promising pipeline assets. Read the full article on Seeking Alpha
Analysis Article • Nov 20

Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Seeking Alpha • Oct 21

Nuvation Bio: Competitive Data In ROS1+ NSCLC, Strong Cash, Smallish Market

Summary Nuvation Bio's Taletrectinib shows promising data in phase 2 trials for ROS1-positive NSCLC, outperforming current market leaders in key metrics like DOR and PFS. Despite a small target market, Taletrectinib's potential $1bn market opportunity and strong financials make NUVB a compelling investment ahead of its PDUFA. Risks include a competitive landscape with established drugs and emerging rivals like NVL-520, which could impact market share. With solid leadership and a strong cash position, NUVB is well-positioned for growth, making it a stock to watch closely. Read the full article on Seeking Alpha
Seeking Alpha • Aug 08

Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024

Summary Nuvation Bio transitioned from early-stage to late-stage biotech with a near-approval, sitting at a $700 million market cap. The main project is taletrectinib, a novel ROS1 inhibitor with high response rates observed in studies, aiming for NDA filing. Financially stable with cash runway of 12-13 quarters, potential for accelerated approval of taletrectinib, but uncertainty in market adoption. Read the full article on Seeking Alpha
Analysis Article • Aug 07

Is Nuvation Bio (NYSE:NUVB) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Jun 20

Nuvation Bio: A Potentially Transformative Acquisition

Summary Nuvation Bio stock has been on a roll since late October, as the shares have roughly tripled since then. The main driver of this rally is the potentially transformative acquisition of AnHeart Therapeutics. This greatly enhanced Nuvation's pipeline and prospects. Analyst firms have a universally positive outlook on the company and its equity as well. In addition, Nuvation is well-funded, with the majority of the stock's market cap represented in cash and marketable securities on the company's balance sheet. An analysis around Nuvation Bio follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Mar 31

Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate

Summary Nuvation Bio has acquired an advanced pipeline candidate, taletrectinib, leading to a surge in market cap approaching $1 billion. Taletrectinib has shown promising clinical activity in treating ROS1-positive non-small cell lung cancer and has Breakthrough Therapy Designation. Nuvation Bio also now has other pipeline candidates, including safusidenib and NUV-868, and has sufficient liquid assets to fund operations for years without help. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has David Hung's remuneration changed compared to Nuvation Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$150m

Mar 31 2026n/an/a

-US$146m

Dec 31 2025US$4mUS$650k

-US$205m

Sep 30 2025n/an/a

-US$217m

Jun 30 2025n/an/a

-US$203m

Mar 31 2025n/an/a

-US$606m

Dec 31 2024US$4mUS$610k

-US$568m

Sep 30 2024n/an/a

-US$532m

Jun 30 2024n/an/a

-US$511m

Mar 31 2024n/an/a

-US$69m

Dec 31 2023US$4mUS$593k

-US$76m

Sep 30 2023n/an/a

-US$83m

Jun 30 2023n/an/a

-US$90m

Mar 31 2023n/an/a

-US$105m

Dec 31 2022US$8mUS$570k

-US$104m

Sep 30 2022n/an/a

-US$108m

Jun 30 2022n/an/a

-US$103m

Mar 31 2022n/an/a

-US$88m

Dec 31 2021US$5mUS$550k

-US$87m

Sep 30 2021n/an/a

-US$75m

Jun 30 2021n/an/a

-US$64m

Mar 31 2021n/an/a

-US$53m

Dec 31 2020US$1mUS$475k

-US$42m

Sep 30 2020n/an/a

-US$38m

Jun 30 2020n/an/a

-US$32m

Mar 31 2020n/an/a

-US$33m

Dec 31 2019US$364kUS$218k

-US$34m

Compensation vs Market: David's total compensation ($USD3.88M) is about average for companies of similar size in the US market ($USD5.18M).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Hung (68 yo)

8.3yrs
Tenure
US$3,876,736
Compensation

Dr. David T. Hung, M.D., serves as Founder, President, Chief Executive Officer and Director at Nuvation Bio Inc since April 2018 and has been it's Chairman of the Board since September 03, 2024. He founded...

Leadership Team

NamePositionTenureCompensationOwnership
David Hung
Founder8.3yrsUS$3.88m17.17%
$ 411.7m
Philippe Sauvage
CFO & Principal Financial Officer1.8yrsUS$1.48m0.015%
$ 369.8k
Gary Hattersley
Chief Scientific Officer7.2yrsUS$1.47mno data
Moses Makunje
VP of Finance and Principal Accounting & Financial Officer2.8yrsno data0.0050%
$ 118.7k
David Hanley
Chief Technical Operations Officerno dataUS$3.31m0.0068%
$ 164.0k
Robert DeVita
Vice President of Corporate Development & Investor Relationsno datano datano data
Stephen Dang
Chief Legal Officer & Corporate Secretaryno datano datano data
Stacy Markel
Chief People Officer6.8yrsno data0.0093%
$ 222.6k
Kerry Wentworth
Chief Regulatory Officer4.1yrsno data0.015%
$ 361.9k
Colleen Sjogren
Chief Commercial Officer2.3yrsUS$2.28m0.024%
$ 573.6k
4.1yrs
Average Tenure
55.5yo
Average Age

Experienced Management: NUVB's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Hung
Founder8.3yrsUS$3.88m17.17%
$ 411.7m
Kathryn Falberg
Independent Director5.8yrsUS$445.00k0.071%
$ 1.7m
Kim Blickenstaff
Independent Director7yrsUS$436.25k0.049%
$ 1.2m
Robert Bazemore
Lead Independent Director6.1yrsUS$483.00k0.0014%
$ 34.1k
Robert Mashal
Independent Director2.6yrsUS$422.50k0.064%
$ 1.5m
Gordon Mills
Member of Scientific Advisory Board3.2yrsno datano data
William Vernon
Independent Director7.2yrsUS$446.00k0.087%
$ 2.1m
Joyce O'Shaughnessy
Member of Scientific Advisory Board3.2yrsno datano data
Mansoor Mirza
Member of Scientific Advisory Board3.2yrsno datano data
Allyson Ocean
Member of Scientific Advisory Board3.2yrsno datano data
Johann de Bono
Member of Scientific Advisory Board3.2yrsno datano data
Wassim Abida
Member of Scientific Advisory Board3.2yrsno datano data
3.2yrs
Average Tenure
65.5yo
Average Age

Experienced Board: NUVB's board of directors are considered experienced (3.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/21 21:32
End of Day Share Price 2026/08/21 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nuvation Bio Inc. is covered by 15 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Clarence PowellBMO Capital Markets Equity Research
Mayank MamtaniB. Riley Securities, Inc.
Silvan TuerkcanCitizens JMP Securities, LLC